References
- Johanson CE, Duncan JA, 3rd, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res 2008; 5:10; PMID:18479516; https://doi.org/10.1186/1743-8454-5-10
- Pardridge WM. Targeted delivery of protein and gene medicines through the blood-brain barrier. Clin Pharmacol Therapeutics 2015; 97:347–61; PMID:25669455; https://doi.org/10.1002/cpt.18
- Bass NH, Lundborg P. Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat: clearance of carboxyl-(14 C)inulin after intrathecal infusion. Brain Res 1973; 52:323–32; PMID:4739806; https://doi.org/10.1016/0006-8993(73)90668-9
- Vladic A, Klarica M, Bulat M. Dynamics of distribution of 3H-inulin between the cerebrospinal fluid compartments. Brain Res 2009; 1248:127–35; PMID:19007752; https://doi.org/10.1016/j.brainres.2008.10.044
- Wu X, Hui AC, Giacomini KM. Formycin B elimination from the cerebrospinal fluid of the rat. Pharmaceutical Res 1993; 10:611–5; PMID:8483848; https://doi.org/10.1023/A:1018970607728
- Ito S, Ueno T, Ohtsuki S, Terasaki T. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1-40) in mouse: involvement of an LRP-1-independent pathway. J Neurochem 2010; 113:1356–63; PMID:20367755; https://doi.org/10.1111/j.1471-4159.2010.06708.x
- Fujiyoshi M, Tachikawa M, Ohtsuki S, Ito S, Uchida Y, Akanuma S, Kamiie J, Hashimoto T, Hosoya K, Iwatsubo T, et al. Amyloid-beta peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier. J Neurochem 2011; 118:407–15; PMID:21585370; https://doi.org/10.1111/j.1471-4159.2011.07311.x
- Bergman I, Burckart GJ, Pohl CR, Venkataramanan R, Barmada MA, Griffin JA, Cheung NK. Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. J Pharmacol Exp Therapeutics 1998; 284:111–5; PMID:9435168
- Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101:466–8; PMID:12393404; https://doi.org/10.1182/blood-2002-06-1636
- Cooper PR, Ciambrone GJ, Kliwinski CM, Maze E, Johnson L, Li Q, Feng Y, Hornby PJ. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Res 2013; 1534:13–21; PMID:23978455; https://doi.org/10.1016/j.brainres.2013.08.035
- Caram-Salas N, Boileau E, Farrington GK, Garber E, Brunette E, Abulrob A, Stanimirovic D. In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis across the blood-brain barrier. Methods Mol Biol (Clifton, NJ) 2011; 763:383–401; PMID:21874466; https://doi.org/10.1007/978-1-61779-191-8_26
- Preston JE. Ageing choroid plexus-cerebrospinal fluid system. Microscopy Res Technique 2001; 52:31–7; PMID:11135446; https://doi.org/10.1002/1097-0029(20010101)52:1<31::AID-JEMT5>3.0.CO;2-T
- Al-Sarraf H, Philip L. Effect of hypertension on the integrity of blood brain and blood CSF barriers, cerebral blood flow and CSF secretion in the rat. Brain Res 2003; 975:179–88; PMID:12763606; https://doi.org/10.1016/S0006-8993(03)02632-5
- Pardridge WM. Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011; 8:7; PMID:21349155; https://doi.org/10.1186/2045-8118-8-7
- Moos T, Morgan EH. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. J Neurochem 2001; 79:119–29; PMID:11595764; https://doi.org/10.1046/j.1471-4159.2001.00541.x
- Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Therapeutics 2000; 292:1048–52; PMID:10688622